| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Schmidt Joshua D. | CLO & Corp Secretary | 200 BELLEVUE PARKWAY, SUITE 300, WILMINGTON | /s/ Ariel E. Greenstein, Attorney-in-Fact for Joshua D. Schmidt | 17 Mar 2026 | 0001889993 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IDCC | Common Stock | Award | +14,286 | +53% | $0.000000* | 41,307 | 15 Mar 2026 | Direct | F1 | |
| transaction | IDCC | Common Stock | Tax liability | -6,604 | -16% | $362.35* | 34,703 | 15 Mar 2026 | Direct | F2 | |
| transaction | IDCC | Common Stock | Disposed to Issuer | -0 | -0% | $362.35* | 34,703 | 15 Mar 2026 | Direct | F3 | |
| transaction | IDCC | Common Stock | Tax liability | -2,811 | -8.1% | $362.35* | 31,892 | 15 Mar 2026 | Direct | F4 | |
| transaction | IDCC | Common Stock | Disposed to Issuer | -2 | -0.01% | $362.35* | 31,889 | 15 Mar 2026 | Direct | F5 | |
| transaction | IDCC | Common Stock | Sale | $214,874 | -624 | -2% | $344.35 | 31,265 | 17 Mar 2026 | Direct | F6, F7 |
| transaction | IDCC | Common Stock | Sale | $344,410 | -998 | -3.2% | $345.10 | 30,267 | 17 Mar 2026 | Direct | F6, F8 |
| transaction | IDCC | Common Stock | Sale | $245,074 | -708 | -2.3% | $346.15 | 29,559 | 17 Mar 2026 | Direct | F6, F9 |
| transaction | IDCC | Common Stock | Sale | $293,336 | -842 | -2.8% | $348.38 | 28,717 | 17 Mar 2026 | Direct | F6, F10 |
| transaction | IDCC | Common Stock | Sale | $370,025 | -1,060 | -3.7% | $349.08 | 27,657 | 17 Mar 2026 | Direct | F6, F11 |
| transaction | IDCC | Common Stock | Sale | $279,444 | -798 | -2.9% | $350.18 | 26,859 | 17 Mar 2026 | Direct | F6, F12 |
| transaction | IDCC | Common Stock | Sale | $188,924 | -538 | -2% | $351.16 | 26,321 | 17 Mar 2026 | Direct | F6, F13 |
| transaction | IDCC | Common Stock | Sale | $42,360 | -120 | -0.46% | $353.00 | 26,201 | 17 Mar 2026 | Direct | F6 |
| transaction | IDCC | Common Stock | Sale | $110,813 | -312 | -1.2% | $355.17 | 25,889 | 17 Mar 2026 | Direct | F6, F14 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transaction reported represents the vesting of awards of performance-based restricted stock units granted to the reporting person on March 31, 2023 pursuant to the company's 2017 Equity Incentive Plan in accordance with the company's long-term compensation program. Based on the achievement level of the 2023 cycle performance goal, 200% of the reporting person's target performance-based restricted stock unit awards, or 13,718 restricted stock units, vested on March 15, 2026 together with 568.3085 additional shares representing accrued dividend equivalent units. |
| F2 | The transaction reported reflects the withholding of restricted stock units in satisfaction of the reporting person's tax liability in connection with the vesting of awards of performance-based restricted stock units described above. |
| F3 | The transaction reported reflects the cash settlement of fractional shares in connection with the vesting of awards of performance-based restricted stock units described above. |
| F4 | The transaction reported reflects the withholding of restricted stock units in satisfaction of the reporting person's tax liability. The restricted stock units were granted to the reporting person on March 31, 2023, March 15, 2024 and March 31, 2025 pursuant to the company's 2017 Equity Incentive Plan in accordance with the company's long-term compensation program and vested on March 15, 2026, together with accrued dividend equivalents. |
| F5 | The transaction reported reflects the cash settlement of fractional shares in connection with the vesting of restricted stock units, as described in the previous footnote. |
| F6 | The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted on March 21, 2025. |
| F7 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $343.60 to $344.56 per share. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the ranges set forth in this footnote and in the other footnotes in this Form 4 indicating a weighted average price. |
| F8 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $344.64 to $345.56 per share. The price reported represents the weighted average price. |
| F9 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $345.70 to $346.56 per share. The price reported represents the weighted average price. |
| F10 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $347.63 to $348.61 per share. The price reported represents the weighted average price. |
| F11 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $348.63 to $349.62 per share. The price reported represents the weighted average price. |
| F12 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $349.77 to $350.75 per share. The price reported represents the weighted average price. |
| F13 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $350.81 to $351.23 per share. The price reported represents the weighted average price. |
| F14 | The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices ranging from $355.04 to $355.55 per share. The price reported represents the weighted average price. |